Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

XNCR Relative to the S&P 500

XNCR Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Xencor, Inc. (NASD:XNCR) seasonal charts above shows that a Buy Date of October 31 and a Sell Date of February 18 has resulted in a geometric average return of 8.19% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 12.09% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

To download XNCR seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: XNCR